Skip to main navigation Skip to search Skip to main content

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy

  • Lauren E. Cain
  • , Michael S. Saag
  • , Maya Petersen
  • , Margaret T. May
  • , Suzanne M. Ingle
  • , Roger Logan
  • , James M. Robins
  • , Sophie Abgrall
  • , Bryan E. Shepherd
  • , Steven G. Deeks
  • , M. John Gill
  • , Giota Touloumi
  • , Georgia Vourli
  • , François Dabis
  • , Marie-Anne Vandenhende
  • , Peter Reiss
  • , Ard van Sighem
  • , Hasina Samji
  • , Robert S. Hogg
  • , Jan Rybniker
  • Caroline A. Sabin, Sophie Jose, Julia del Amo, Santiago Moreno, Benigno Rodríguez, Alessandro Cozzi-Lepri, Stephen L. Boswell, Christoph Stephan, Santiago Pérez-Hoyos, Inma Jarrin, Jodie L. Guest, Antonella D'Arminio Monforte, Andrea Antinori, Richard Moore, Colin Nj Campbell, Jordi Casabona, Laurence Meyer, Rémonie Seng, Andrew N. Phillips, Heiner C. Bucher, Matthias Egger, Michael J. Mugavero, Richard Haubrich, Elvin H. Geng, Ashley Olson, Joseph J. Eron, Sonia Napravnik, Mari M. Kitahata, Stephen E. van Rompaey, Ramón Teira, Amy C. Justice, Janet P. Tate, Dominique Costagliola, Jonathan Ac Sterne, Miguel A. Hernán

Research output: Contribution to journalArticleAcademicpeer-review

27 Downloads (Pure)

Abstract

When a clinical treatment fails or shows suboptimal results, the question of when to switch to another treatment arises. Treatment switching strategies are often dynamic because the time of switching depends on the evolution of an individual's time-varying covariates. Dynamic strategies can be directly compared in randomized trials. For example, HIV-infected individuals receiving antiretroviral therapy could be randomized to switching therapy within 90 days of HIV-1 RNA crossing above a threshold of either 400 copies/ml (tight-control strategy) or 1000 copies/ml (loose-control strategy). We review an approach to emulate a randomized trial of dynamic switching strategies using observational data from the Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. We estimated the comparative effect of tight-control vs. loose-control strategies on death and AIDS or death via inverse-probability weighting. Of 43 803 individuals who initiated an eligible antiretroviral therapy regimen in 2002 or later, 2001 met the baseline inclusion criteria for the mortality analysis and 1641 for the AIDS or death analysis. There were 21 deaths and 33 AIDS or death events in the tight-control group, and 28 deaths and 41 AIDS or death events in the loose-control group. Compared with tight control, the adjusted hazard ratios (95% confidence interval) for loose control were 1.10 (0.73, 1.66) for death, and 1.04 (0.86, 1.27) for AIDS or death. Although our effective sample sizes were small and our estimates imprecise, the described methodological approach can serve as an example for future analyses
Original languageEnglish
Pages (from-to)2038-2049
JournalInternational journal of epidemiology
Volume45
Issue number6
Early online date2016
DOIs
Publication statusPublished - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy'. Together they form a unique fingerprint.

Cite this